|
1
|
Alipieva K, Korkina L, Orhan IE and
Georgiev MI: Verbascoside-a review of its occurrence,
(bio)synthesis and pharmacological significance. Biotechnol Adv.
32:1065–1076. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Song HS and Sim SS: Acteoside inhibits
alpha-MSH-induced melanin production in B16 melanoma cells by
inactivation of adenyl cyclase. J Pharm Pharmacol. 61:1347–1351.
2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Akdemir Z, Kahraman C, Tatlı II, Küpeli
Akkol E, Süntar I and Keles H: Bioassay-guided isolation of
anti-inflammatory, antinociceptive and wound healer glycosides from
the flowers of Verbascum mucronatum Lam. J Ethnopharmacol.
136:436–443. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Georgiev M, Pastore S, Lulli D, Alipieva
K, Kostyuk V, Potapovich A, Panetta M and Korkina L: Verbascum
xanthophoeniceum-derived phenylethanoid glycosides are potent
inhibitors of inflammatory chemokines in dormant and
interferon-gamma-stimulated human keratinocytes. J Ethnopharmacol.
144:754–760. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wartenberg M, Budde P, De Mareés M,
Grünheck F, Tsang SY, Huang Y, Chen ZY, Hescheler J and Sauer H:
Inhibition of tumor-induced angiogenesis and
matrix-metalloproteinase expression in confrontation cultures of
embryoid bodies and tumor spheroids by plant ingredients used in
traditional chinese medicine. Lab Invest. 83:87–98. 2003.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Attia YM, El-Kersh DM, Wagdy HA and
Elmazar MM: Verbascoside: Identification, quantification, and
potential sensitization of colorectal cancer cells to 5-FU by
targeting PI3K/AKT pathway. Sci Rep. 8(16939)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Qin YZ and Huang XJ: Molecular detection
of BCR-ABL in chronic myeloid leukemia. Methods Mol Biol.
1465:1–15. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhang F, Jia Z, Deng Z, Wei Y, Zheng R and
Yu L: In vitro modulation of telomerase activity, telomere length
and cell cycle in MKN45 cells by verbascoside. Planta Med.
68:115–118. 2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lee KW, Kim HJ, Lee YS, Park HJ, Choi JW,
Ha J and Lee KT: Acteoside inhibits human promyelocytic HL-60
leukemia cell proliferation via inducing cell cycle arrest at G0/G1
phase and differentiation into monocyte. Carcinogenesis.
28:1928–1936. 2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bardellini E, Amadori F, Schumacher RF,
D'Ippolito C, Porta F and Majorana A: Efficacy of a solution
composed by verbascoside, polyvinylpyrrolidone (PVP) and sodium
hyaluronate in the treatment of chemotherapy-induced oral mucositis
in children with acute lymphoblastic leukemia. J Pediatr Hematol
Oncol. 38:559–562. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yilmaz M and Jabbour E: Tyrosine kinase
inhibitors early in the disease course: Lessons from chronic
myelogenous leukemia. Semin Oncol. 42:876–886. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Assouline S and Lipton JH: Monitoring
response and resistance to treatment in chronic myeloid leukemia.
Curr Oncol. 18:e71–e83. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Jabbour EJ, Cortes JE and Kantarjian HM:
Resistance to tyrosine kinase inhibition therapy for chronic
myelogenous leukemia: A clinical perspective and emerging treatment
options. Clin Lymphoma Myeloma Leuk. 13:515–529. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bixby D and Talpaz M: Mechanisms of
resistance to tyrosine kinase inhibitors in chronic myeloid
leukemia and recent therapeutic strategies to overcome resistance.
Hematology Am Soc Hematol Educ Program. 461–476. 2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mitchell R, Hopcroft LEM, Baquero P, Allan
EK, Hewit K, James D, Hamilton G, Mukhopadhyay A, O'Prey J, Hair A,
et al: Targeting BCR-ABL-independent TKI resistance in chronic
myeloid leukemia by mTOR and autophagy inhibition. J Natl Cancer
Inst. 110:467–478. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Olivieri A and Manzione L: Dasatinib: A
new step in molecular target therapy. Ann Oncol. 18 (Suppl
6):vi42–vi46. 2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Damiano S, Montagnaro S, Puzio MV,
Severino L, Pagnini U, Barbarino M, Cesari D, Giordano A, Florio S
and Ciarcia R: Effects of antioxidants on apoptosis induced by
dasatinib and nilotinib in K562 cells. J Cell Biochem.
119:4845–4854. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Welner RS, Amabile G, Bararia D, Czibere
A, Yang H, Zhang H, Pontes LL, Ye M, Levantini E, Di Ruscio A, et
al: Treatment of chronic myelogenous leukemia by blocking cytokine
alterations found in normal stem and progenitor cells. Cancer Cell.
27:671–681. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
González-Flores D, Rodriguez AB and
Pariente JA: TNFα-induced apoptosis in human myeloid cell lines
HL-60 and K562 is dependent of intracellular ROS generation. Mol
Cell Biochem. 390:281–287. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yu C, Krystal G, Varticovksi L, McKinstry
R, Rahmani M, Dent P and Grant S: Pharmacologic mitogen-activated
protein/extracellular signal-regulated kinase
kinase/mitogen-activated protein kinase inhibitors interact
synergistically with STI571 to induce apoptosis in
Bcr/Abl-expressing human leukemia cells. Cancer Res. 62:188–199.
2002.PubMed/NCBI
|
|
21
|
Wu GS: Role of mitogen-activated protein
kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev.
26:579–585. 2007.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Deininger MW and Druker BJ: Specific
targeted therapy of chronic myelogenous leukemia with imatinib.
Pharmacol Rev. 55:401–423. 2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shah NP, Kasap C, Weier C, Balbas M,
Nicoll JM, Bleickardt E, Nicaise C and Sawyers CL: Transient potent
BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia
cells irreversibly to apoptosis. Cancer Cell. 14:485–493.
2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
García LT, Leal AF, Morenoa ÉM, Stashenko
EE and Arteaga J: Differential anti-proliferative effect on K562
leukemia cells of Lippia alba (Verbenaceae) essential oils
produced under diverse growing, collection and extraction
conditions. sInd Crops Prod. 96:140–148. 2017.
|
|
25
|
Oukerrou MA, Tilaoui M, Mouse HA, Bouchmaa
N and Zyad A: Differential cytotoxic activity of essential oil of
Lippia citriodora from different regions in morocco. Chem
Biodivers. 14:2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yang X, Feng W, Wang R, Yang F, Wang L,
Chen S, Ru Y, Cheng T and Zheng G: Repolarizing heterogeneous
leukemia-associated macrophages with more M1 characteristics
eliminates their pro-leukemic effects. Oncoimmunology.
7(e1412910)2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Dorey K, Engen JR, Kretzschmar J, Wilm M,
Neubauer G, Schindler T and Superti-Furga G: Phosphorylation and
structure-based functional studies reveal a positive and a negative
role for the activation loop of the c-Abl tyrosine kinase.
Oncogene. 20:8075–8084. 2001.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Baykal-Köse S, Acikgoz E, Yavuz AS, Gönül
Geyik Ö, Ateş H, Sezerman OU, Özsan GH and Yüce Z: Adaptive
phenotypic modulations lead to therapy resistance in chronic
myeloid leukemia cells. PLoS One. 15(e0229104)2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Erel O: A novel automated method to
measure total antioxidant response against potent free radical
reactions. Clin Biochem. 37:112–119. 2004.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Olive PL and Banáth JP: The comet assay: A
method to measure DNA damage in individual cells. Nat Protoc.
1:23–29. 2006.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Modi H, Li L, Chu S, Rossi J, Yee JK and
Bhatia R: Inhibition of Grb2 expression demonstrates an important
role in BCR-ABL-mediated MAPK activation and transformation of
primary human hematopoietic cells. Leukemia. 25:305–312.
2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Flis S and Chojnacki T: Chronic
myelogenous leukemia, a still unsolved problem: Pitfalls and new
therapeutic possibilities. Drug Des Devel Ther. 13:825–843.
2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Alfarouk KO, Stock CM, Taylor S, Walsh M,
Muddathir AK, Verduzco D, Bashir AH, Mohammed OY, Elhassan GO,
Harguindey S, et al: Resistance to cancer chemotherapy: Failure in
drug response from ADME to P-gp. Cancer Cell Int.
15(71)2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ma Z, Zhao X, Jiang C, Yu J, Wu J and Zeng
X: Gold nanoshells with verbascoside induce the apoptosis of
drug-resistant leukemia cells through caspases pathway and inhibit
tumor growth. J Nanosci Nanotechnol. 16:7118–7124. 2016.
|
|
35
|
Dalgıç CT, Kaymaz BT, Özkan MC, Dalmızrak
A, Şahin F and Saydam G: Investigating the role of JAK/STAT pathway
on dasatinib-induced apoptosis for CML cell model K562. Clin
Lymphoma Myeloma Leuk. 15 (Suppl):S161–S166. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
De Martino L, D'Arena G, Minervini MM,
Deaglio S, Fusco BM, Cascavilla N and De*Feo V: Verbena officinalis
essential oil and its component citral as apoptotic-inducing agent
in chronic lymphocytic leukemia. Int J Immunopathol Pharmacol.
22:1097–1104. 2009.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ma L, Xu Z, Wang J, Zhu Z, Lin G, Jiang L,
Lu X and Zou C: Matrine inhibits BCR/ABL mediated ERK/MAPK pathway
in human leukemia cells. Oncotarget. 8:108880–108889.
2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Baykal-Kose S and Yalcin P: Altered
apoptotic protein expressions characterize the survival of
Bcr-Abl-independent drug-resistant chronic myeloid leukemia cell
line. 1 J Basic Clin Health Sci. 1:1–5. 2021.
|
|
39
|
Dumka D, Puri P, Carayol N, Lumby C,
Balachandran H, Schuster K, Verma AK, Terada LS, Platanias LC and
Parmar S: Activation of the p38 Map kinase pathway is essential for
the antileukemic effects of dasatinib. Leuk Lymphoma. 50:2017–2029.
2009.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Aceves-Luquero CI, Agarwal A,
Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso
Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya
EM, Moreno Gimeno I, et al: ERK2, but not ERK1, mediates acquired
and ‘de novo’ resistance to imatinib mesylate: implication for CML
therapy. PLoS One. 4(e6124)2009.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Pesce M, Franceschelli S, Ferrone A, De
Lutiis MA, Patruno A, Grilli A, Felaco M and Speranza L:
Verbascoside down-regulates some pro-inflammatory signal
transduction pathways by increasing the activity of tyrosine
phosphatase SHP-1 in the U937 cell line. J Cell Mol Med.
19:1548–1556. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Puissant A, Dufies M, Fenouille N, Ben
Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Chéli
Y, et al: Imatinib triggers mesenchymal-like conversion of CML
cells associated with increased aggressiveness. J Mol Cell Biol.
4:207–220. 2012.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Cort A, Ozben T, Saso L, De Luca C and
Korkina L: Redox control of multidrug resistance and its possible
modulation by antioxidants. Oxid Med Cell Longev.
2016(4251912)2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Vasincu A, Neophytou CM, Luca SV,
Skalicka-Woźniak K, Miron A and Constantinou AI:
6-O-(3',4'-di-O-trans-cinnamoyl)-α-l-rhamnopyranosylcatalpol and
verbascoside: Cytotoxicity, cell cycle kinetics, apoptosis, and ROS
production evaluation in tumor cells. J Biochem Mol Toxicol.
34(e22443)2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wang L, Wang M, Dou H, Lin W and Zou L:
Sirtuin 1 inhibits lipopolysaccharide-induced inflammation in
chronic myelogenous leukemia k562 cells through interacting with
the Toll-like receptor 4-nuclear factor kappa B-reactive oxygen
species signaling axis. Cancer Cell Int. 20(73)2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Speranza L, Franceschelli S, Pesce M,
Reale M, Menghini L, Vinciguerra I, De Lutiis MA, Felaco M and
Grilli A: Antiinflammatory effects in THP-1 cells treated with
verbascoside. Phytother Res. 24:1398–1404. 2010.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Huang YH, Henriques ST, Wang CK,
Thorstholm L, Daly NL, Kaas Q and Craik DJ: Design of
substrate-based BCR-ABL kinase inhibitors using the cyclotide
scaffold. Sci Rep. 5(12974)2015.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Trela E, Glowacki S and Błasiak J: Therapy
of chronic myeloid leukemia: Twilight of the imatinib era? ISRN
Oncol. 2014(596483)2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Rossari F, Minutolo F and Orciuolo E:
Past, present, and future of Bcr-Abl inhibitors: From chemical
development to clinical efficacy. J Hematol Oncol.
11(84)2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Aggul AG, Taslimi P, Kuzu M, Uzun N,
Bilginer S and Gulcin I: Oleuropein and verbascoside-their
inhibition effects on carbonic anhydrase and molecular docking
studies. J Oleo Sci. 70:1275–1283. 2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Cheimonidi C, Samara P, Polychronopoulos
P, Tsakiri EN, Nikou T, Myrianthopoulos V, Sakellaropoulos T,
Zoumpourlis V, Mikros E, Papassideri I, et al: Selective
cytotoxicity of the herbal substance acteoside against tumor cells
and its mechanistic insights. Redox Biol. 16:169–178.
2018.PubMed/NCBI View Article : Google Scholar
|
